Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Treatment of ALK whose disease has progressed after treatment with crizotinib and at least one other ALK inhibitor, or after treatment with alectinib or ceritinib as the first ALK inhibitor Positive metastatic non-small cell lung cancer (NSCLC) patients.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.